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Abstract
Background: Ertapenem (preferred choice for ESBL-producing organisms) use exhibited an increasing trend from
2006 to 2008. As extensive use of ertapenem might induce the mutation of resistant bacteria strains to ertapenem,
we aimed to assess the appropriateness and impact of ertapenem-use, on ESBL production, the trends of
gram-negative bacterial resistance and on the utilization of other antibiotics in our institution.
Methods: Inpatients who received a dose of ertapenem during 1 January 2006 to 31 December 2008, were
reviewed. Pertinent patient clinical data was extracted from the pharmacy databases and assessed for appropriateness
based on dose and indication. Relevant data from Network for Antimicrobial Resistance Surveillance (Singapore)
(NARSS) was extracted, to cross-correlate with ertapenem via time series to assess its impact on hospital epidemiology,
trends of gram-negative resistance and consumption of other antibiotics from 2006 to mid-2010.
Results: 906 cases were reviewed. Ertapenem therapy was appropriate in 72.4% (93.7% success rate). CNS adverse events
were noted in 3.2%. Readmission rate (30-day) due to re-infection (same pathogen) was 5.5%. Fifty cases had cultures
growing Pseudomonas aeruginosa within 30 days of ertapenem initiation, with 25 cases growing carbapenem-resistant
Pseudomonas aeruginosa.
Ertapenem use increased from 0.45 DDD/100 patient days in 2006 to 1.2 DDD/100 patient days in mid-2010.
Overall, the increasing trend of ertapenem consumption correlated with 1) increasing incidence-densities of
ciprofloxacin-resistant/cephalosporin-resistant E. coli at zero time lag; 2) increasing incidence-densities of
ertapenem-resistant Escherichia. coli and Klebsiella spp. at zero time lag; 3) increasing incidence-density of
carbapenem-resistant Pseudomonas aeruginosa, at zero time lag.
Increasing ertapenem consumption was significantly correlated with decreasing consumption of cefepime (R2 = 0.37344)
3 months later. It was significantly correlated with a decrease in imipenem consumption (R2 = 0.31081), with no time lag
but was correlated with subsequent increasing consumption of meropenem (R2 = 0.4092) 6 months later.
Conclusion: Ertapenem use was appropriate. Increasing Ertapenem consumption did not result in a decreasing trend of
ESBL producing enterobacteriaceae and could result in the selection for multi-drug resistant bacteria.
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Background
Antibiotic options in the treatment of extended spectrum
beta-lactamases (ESBL)-producing organisms are ex-
tremely limited. Carbapenems are the treatment of choice
for serious infections due to ESBL producing organisms [1].
Ertapenem, which belongs to the class of carbapenems,
possesses antibacterial activity against ESBL-producing
enterobacteriaceae and Haemophilus species and not the
nonfermenters [2]. Hence, it is the preferred carba-
penem choice for infections caused by ESBL-producing
organisms currently.
Ertapenem has a longer half-life than the older carba-
penems, hence allowing for once-daily administration
[3,4]. This allows the patients to utilize the convenience of
Outpatient Parenteral Antibiotic Therapy (OPAT) clinic in
our institution, Singapore General Hospital (SGH), which
reduces length of hospitalization in our hospital. Though
ertapenem is in the hospital formulary since 2006, written
or verbal approval for use has to be sought with the Infec-
tious Diseases physicians. The use of ertapenem exhibited
an increasing trend from 2006 to 2008. In July 2009,
this prescribing restriction was removed. Henceforth, erta-
penem is approved for use by any physicians if it is
culture-directed (presence of ESBL-producing enterobac-
teriaceae evident by 3rd generation cephalosporins resist-
ance) or for empiric treatment of suspected ESBL
infections in patient who has a history of ESBL infections
in the past 90 days. Every ertapenem case will be subjected
to within 24-hour concurrent feedback audit by Anti-
microbial Stewardship team.
In SGH, where extended spectrum beta-lactamases are
prevalent, there is a gradual rise in the use of carbapenems,
which could bring about acquired resistance. Resistance
to carbapenems is due to changes in outer membrane
proteins, efflux pumps and potent metalloenzymes that
cause hydrolysis of carbapenems [5]. Thus, with the
introduction of ertapenem into the formulary, it was
thought that we could preserve the use of the other
anti-pseudomonal carbapenems for infections involving
Pseudomonas aeruginosa.
On the other hand, there are concerns that extensive
use of ertapenem may induce the mutation of resistant
bacteria strains to ertapenem and select out Pseudo-
monas aeruginosa [5,6] strains that might have cross-
resistance to other anti-pseudomonal carbapenems. While
some studies have shown that ertapenem use was not asso-
ciated with carbapenem-resistant Pseudomonas aeruginosa,
these only looked at pharmacy purchasing databases,
which may not necessarily reflect actual ertapenem pre-
scription [7-10]. Moreover, none of the studies evaluated
ertapenem use and development of gram-negative bacterial
resistance at patient-level.
Hence, we evaluated the appropriateness and out-
comes of ertapenem use in SGH from 2006 to 2008 and
assessed the impact of ertapenem on the hospital’s
epidemiology, especially ESBL production, trends of gram-
negative bacterial resistance, and utilization of other




This study was a single-centered, retrospective study
which was approved by the SingHealth Institutional Re-
view Board.
Inclusion criteria and data collection
Patients were included in the study if they received at least
one dose of ertapenem in Singapore General Hospital be-
tween 1 January 2006 and 31 December 2008 and those
who were solely prescribed ertapenem as OPAT were ex-
cluded. Patient demographics and treatment related data
(details of ertapenem and prior antibiotic therapy, clinical
and microbiological outcomes) were extracted from the
hospital’s medical records and pharmacy database.
Appropriateness of ertapenem use
Ertapenem use was deemed appropriate only if criteria
for both indication and dose were met. The appropriate
indications for ertapenem include i) definitive therapy
for ESBL producing enterobacteriaceae or non-ESBL
producing enterobacteriaceae in penicillin allergic pa-
tients, where susceptibility to ertapenem is confirmed
and there were limited therapeutic options left, and ii)
empiric ertapenem therapy for septic patients who had
prior hospitalization with positive cultures for ESBL
producing enterobacteriaceae within the last 90 days.
Enterobacteriaceae, that are ESBL producing, are charac-
terized by their resistance to 3rd generation cephalosporins
(e.g. ceftriaxone and ceftazidime) [11]. ESBL production
was also confirmed using double-disk diffusion method
[1]. Use of ertapenem for i) Pseudomonas aeruginosa and
Acinetobacter spp. infections, ii) primary bacteremia and
iii) central nervous system infections (CNS) are defined as
being inappropriate. Ertapenem dosing was considered ap-
propriate if dose was adjusted according to patients’ renal
function (calculated using the Cockcroft-Gault equation)
[12], where dose has to be reduced from 1g once daily to
500mg once daily in patients with creatinine clearance less
than 30ml/min.
Outcome analysis and definitions
The clinical efficacy and safety of ertapenem use was
assessed and recorded, from the first day to the last day
of ertapenem therapy. Treatment outcomes of ertape-
nem such as i) presence of clinical improvement and ii)
presence of microbiological eradication of causative
organism(s) were evaluated. Clinical improvement was
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defined as normalization of blood counts, inflammatory
markers, temperature and vital signs. Microbiological
eradication was concluded when there was no further bac-
terial growth of causative organism(s). Where repeat cul-
tures and sensitivities were not performed, eradication was
presumed if the patient was discharged clinically well.
Hence, treatment success was defined as i) presence of
microbiological eradication (or presumed microbiological
eradication) primarily, with and without clinical improve-
ment or ii) presence of clinical improvement (followed by
home discharge), if follow up cultures were absent. New
infections were defined as infections with different patho-
gens, that occurred after ertapenem initiation; excluding
those that were present prior to ertapenem therapy.
Other outcomes used to assess treatment efficacy in-
clude 30-day mortality (from first date of ertapenem use)
and discharge status (death, home or nursing home). Hos-
pital readmission and re-infection with the same causative
organism within 30 days were also evaluated.
Impact of ertapenem on micro-ecology and antibiotic
utilization
To assess the association of ertapenem consumption with
consumption of other broad-spectrum antibiotics, ertape-
nem utilization over a course of 4.5 years from 2006 to
mid-2010 was correlated with the consumption of selected
antibiotics (ciprofloxacin, ceftriaxone, cefepime and anti-
pseudomonal carbapenems). All utilization data, defined
as defined daily dose (DDD) per 100 inpatient-days of
antibiotic, which corresponds to the assumed average daily
maintenance dose, was obtained from Network for Anti-
microbial Resistance Surveillance (Singapore) (NARSS)
[13-16]. NARSS was established in December 2005 to
conduct prospective surveillance of antibiotic resistance
and prescription in Singapore public hospitals, with the
aim of analyzing trends over time. Antibiotic resistance
and prescription data in NARSS was obtained from the
hospital laboratory information systems and pharmacy
prescription databases.
Ertapenem consumption over the same period of time
was also compared to the incidence density of certain mi-
croorganisms per 1000 inpatient-days (PD) reported in
NARSS [15-21] to evaluate impact of ertapenem consump-
tion on gram-negative resistance trends. These microorgan-
isms include a) ciprofloxacin-resistant Escherichia coli and
Klebsiella spp., b) cephalosporin-resistant Escherichia coli
and Klebsiella spp. isolates. Incidence densities of the fol-
lowing microorganisms were measured as number of cases
per 10,000 PD: a) ertapenem-resistant Klebsiella spp. and
Escherichia coli, b) carbapenem-resistant Acinetobacter
baumannii, c) carbapenem-resistant Pseudomonas aerugi-
nosa. These microorganisms were reported in NARSS be-
cause of their potential adverse impact on nosocomial
infections and public health [13-16].
Statistical analysis
Univariate analysis was done to describe the patients’
demographics. Time series analysis was first performed
for trend of antibiotic prescription and antimicrobial
resistant bacteria over time; and if significant, cross-
correlation analysis was then performed to measure
the impact of ertapenem on micro-ecology and anti-




A total of 929 patients were treated with ertapenem be-
tween 1 January 2006 and 31 December 2008. Twenty-
three patients were excluded because of unavailability of
case notes. Hence, only 906 patients were analyzed. The
mean duration of hospital stay was 36.55 ± 45.53 days.
The median age of cases was 63.00 ± 15.74 years. More
than half of the patients had underlying hypertension, dia-
betes mellitus and/or hyperlipidemia (Figure 1).
Table 1 described the types of infections for which
ertapenem was used in the study patients, and these in-
fections may or may not be appropriate for ertapenem
use. Urinary tract infection and bacteremia were the two
main infections for ertapenem use (Table 1). Out of the
306 cases that were due to bacteremia, 134 cases were
due to primary bacteremia while 172 cases were due to
secondary bacteremia with known sources. The main
culture sites were: urine (35.2%), blood (33.8%), wound
(23.8%), other body fluids (11.1%) and sputum (6.2%).
Approximately 7 out of 10 cases had ESBL infections
from Escherichia coli and Klebsiella spp. (Figure 2).
Appropriateness
Approximately 72.4% of the cases fulfilled the criteria for
appropriate ertapenem use. While 86.0% cases (n = 779)














Figure 1 Medical Co-morbidities.
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were empirical and prophylactic, respectively. Of the
culture-directed cases, 46.0% were de-escalation from
broader carbapenems to ertapenem (359 out of 779
culture-directed cases). Cephalosporins (47.6%) were
the most common beta-lactam antibiotics used before
ertapenem, followed by anti-pseudomonal carbapenems
(39.6%) such as imipenem and meropenem (Figure 3). As
ertapenem is not indicated for surgical prophylaxis, none
of the prophylaxis cases were included in the efficacy
(under outcomes) analysis. The median duration of
ertapenem therapy was 8 (1 – 75) days.
Outcomes analysis
Safety of ertapenem treatment
Adverse events related to or suspected to be induced by
ertapenem were noted in 46 cases (5.1%), with the major-
ity of those involving the CNS (n = 29) (Table 3). Seizures
and confusion occurred in 9 (1.0%) and 20 cases (2.2%) re-
spectively. Of the 9 cases with seizures, 4 cases (44.4%) oc-
curred in patients with underlying epilepsy (Table 3),
where only one was inappropriately dosed. In 6 of these 9
cases (66.7%), patients had renal impairment.
Efficacy
The number of cases which were included for efficacy ana-
lysis was 899. Treatment success was observed in 842 cases
(93.7%). Out of the 57 treatment failures, 14 cases were pre-
scribed ertapenem for bacteremia; of which 8 and 6 cases
were primary and secondary bacteremia respectively. One
hundred and two cases (11.3%) had new infections, with 58
cases (56.9%) occurring during ertapenem therapy and 44
cases (43.1%) occurring after discontinuation of therapy.
Out of the 102 cases with new infections, 8 and 4 were
Table 1 Types of infections for which ertapenem was
used
No. of Cases (%)
Bacteremia 306 (33.8)
Urinary tract infection 337 (37.2)
Intra-abdominal infection 141 (15.6)
Pneumonia 74 (8.2)
Skin and soft tissue infection 145 (16.0)
Others* 64 (7.1)
*Other infections for which ertapenem was used include: line sepsis,
osteomyelitis, graft infections, surgical prophylaxis and CNS infections. Patients
may have had more than one type of infection for ertapenem use. These




















Figure 2 Types of Microorganisms Isolated.
Table 2 Details of ertapenem therapy
No. of
Cases (%)





500 milligrams once daily 149 (16.5)
1 gram every other day 16 (1.8)
1 gram once daily 730 (80.6)
1 gram stat 6 (0.6)
Others^ 5 (0.5)
Median duration of therapy (days) (range) 8 (1 – 75)
Prescribed as outpatient antibiotic therapy (OPAT#) 185 (20.4)
Other antibiotic use in the same admission
Concurrent antibiotic therapy 566 (62.5)
Previous antibiotic therapy 778 (85.9)
Previous beta-lactam use * 754 (83.3)
^Others includes 250 milligrams once daily, 1 gram three times a week.
#These patients only include those that continue OPAT from hospitalization.
*Examples of beta-lactams include amoxicillin-clavulanic acid, ceftriaxone,
cefepime and piperacillin-tazobactam.
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primary and secondary bacteremia respectively. Thirty-five
cases with new infections were polymicrobial in nature.
Mortality and re-admission
The proportion of live-discharges was 87.9% (n = 796)
(Table 4). Of which, 20.4% (n = 185) were readmitted
within 30 days post-discharge with 5.5% (n = 44) being
re-infected with the same causative microorganism.
Seventy-three (36 primary and 37 secondary) out of 306
cases with bacteremia were readmitted within 30 days.
Out of these 73 cases, 3 were readmitted with primary
bacteremia and 4 were readmitted with secondary
bacteremia. Overall mortality rate within 30 days from
the first day of ertapenem treatment was 10.7% (n = 97).
Resistance development
Fifty cases (5.5%) had cultures growing Pseudomonas aer-
uginosa within 30 days from initiation of ertapenem ther-
apy (Table 5) with 25 cases growing carbapenem-resistant
Pseudomonas aeruginosa.
Correlation of ertapenem consumption with incidence of
antibiotic-resistant bacteria
Ertapenem use increased from 0.45 DDD/100 PD in 2006
to 1.2 DDD/100 PD in mid-2010. Cross-correlation ana-
lysis of ertapenem consumption to microorganisms with
significant trend changes in incidence rates from 2006 to
mid-2010 were performed and reported in Table 6.
Incidence-density of ciprofloxacin-resistant Escherichia
coli increased from 3.2 cases per 1000 PD in 2006 to 3.7
cases per 1000 PD in mid-2010; the same increasing trend
was also observed in cephalosporin-resistant Escherichia
coli (1.6 to 2.0 cases per 1000 PD). Increasing ertapenem
consumption correlated, at zero time lag, with increasing
incidence-density of 1) ciprofloxacin-resistant Escherichia
coli (R2 = 0.2862) insignificantly and 2) cephalosporin-
resistant Escherichia coli (R2 = 0.4442) significantly. Con-
versely, ciprofloxacin and ceftriaxone-resistant Klebsiella
spp incidence densities decreased independently, before
the increase in ertapenem consumption. There was
approximately 50% decrease in incidence-density of
ciprofloxacin-resistant Klebsiella spp. (2.2 to 1.1 cases per
1000 PD) and ceftriaxone-resistant Klebsiella spp. (2.4 to
1.5 cases per 1000 PD) from 2006 to mid-2010.
An increase in both ertapenem-resistant Escherichia coli
and Klebsiella spp. was observed between 2006 and
mid-2010. Increasing ertapenem consumption correlated
significantly with increasing incidence-density of ertapenem-
resistant Escherichia coli (0.02 to 0.25 cases per 10,000 PD,
R2 = 0.5103) and insignificantly with ertapenem-resistant
Klebsiella spp.(0.4 to 1.0 cases per 10,000 PD, R2 = 0.2755)
at zero time lag. The increasing trend of ertapenem con-
sumption correlated with increasing incidence-density




































Figure 3 Previous & Concurrent Antibiotic Therapy.
Table 3 Adverse drug reactions
Adverse drug reaction No. of
Patients (%)
Seizures 9 (1.0)
Seizures occurring in those with previous history of
epilepsy
4 (0.4)
Central nervous system side effects (excluding seizures) 20 (2.2)
Gastrointestinal side effects 3 (0.3)
Others* 10 (1.1)
*Other adverse drug reactions included drug fever, eosinophilia and urticaria.
Table 4 Mortality and re-admission
Discharge status Frequency (%)
Death 97 (10.7)
Home 724 (79.9)
Nursing home 72 (7.9)
Hospital readmission (within 30-day of
discharge)
185 (20.4)
Re-infection with the same causative
microorganism (in relation to hospital re-admission)
44 (5.5)
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increasing statistical trend (0.25 to 0.35 cases per 10,000
PD, R2 = 0.3190), at zero time lag (Figure 4).
Correlation of ertapenem consumption with consumption
of other antibiotics
Ciprofloxacin use slightly increased from 1.17 DDD/100
PD in 2006 to 1.3 DDD/100 PD in mid-2010. Similarly,
ceftriaxone use increased from 5.61 DDD/100 PD in 2006
to 12.5 DDD/100 PD in mid-2010. The increasing con-
sumption of ciprofloxacin (R2 = 0.10093) and ceftriaxone
(R2 = 0.22043) before, was insignificantly correlated with
subsequent increasing consumption of ertapenem (Table 7).
However, the increasing ertapenem consumption was
correlated with subsequent decreasing consumption
of cefepime 3 months later at increasing statistical
trend, from 5.4 DDD/100 PD in 2006 to 4.7 DDD/100
PD (R2 = 0.37344). Meropenem use increased from 2.0
DDD/100 PD in 2006 to 3.2 DDD/100 PD in mid-2010,
but the converse was true for imipenem, where its use
decreased from 1.8 DDD/100 PD to 0.7 DDD/100 PD in
mid-2010 (Figure 5). The increase in ertapenem con-
sumption was correlated with a decrease in imipenem
consumption significantly (R2 = 0.31081), with no time
lag and was correlated with subsequent increasing con-
sumption of meropenem (R2 = 0.4092) 6 months later.
Discussion
We had evaluated the appropriateness and outcomes of
ertapenem use in SGH from 2006 to 2008 and assessed
the impact of ertapenem on the institution’s ESBL
production, and trends of gram-negative bacterial resist-
ance, and utilization of other antibiotics from 2006 to
mid-2010 (4.5 years total and 1.5 years after the evaluation
of use). The rate of appropriateness of ertapenem use was
high. Most of our ertapenem use was culture-directed. As
cephalosporins were the most common antibiotics that
were administered prior to ertapenem (47.6%), escalation
from cephalosporins to ertapenem suggested that ESBL
microorganisms (likely mainly ESBL producing E. coli in
our institution) could have been selected out with its
widespread use, since the increased prevalence of ESBL in-
fections could result from an increased consumption of
3rd generation cephalosporins [22].
While ertapenem treatment success rates were high in
SGH, seizures occurred in 1.0% of the patients (n = 9),
which was higher than the 0.5% reported in post market-
ing surveillance reports [3]. This could be due to the
existing concurrent medical conditions of these patients,
whereby 4 out of 9 patients (44.4%) had pre-existing epi-
lepsy history. Two patients had a history of multiple
cerebral vascular accidents; another was concurrently on
morphine, which may potentiate seizures [23]; and one
had a recent seizure episode that may be secondary to
hypoglycemia. In addition, two-third of these patients
had renal impairment, which suggested that seizures
may be potentiated by drug accumulation due to de-
creased clearance.
Primary bacteremia is an inappropriate indication for
ertapenem use in our study, due to limited evidence. Sec-
ondary bacteremia from an infective source, however, is an
Table 5 Microorganisms isolated within 30 days from the start date of ertapenem therapy
Microorganism* Infection with new microorganism




Pseudomonas aeruginosa 50 (5.5) 25 (2.8)
Stenotrophomonas maltophila 21 (2.3) 21 (2.3)**
Acinetobacter baumannii 27 (3.0) 20 (2.2)
Enterobacteriaceae (such as Klebsiella spp., E. coli, Proteus spp.) with ESBL production 41 (4.5) 8 (0.9)
*More than one microorganism was isolated in some cases within 30 days from initiation of ertapenem therapy.
**Carbapenem sensitivity testing was not performed. However, Stenotrophomonas maltophila is intrinsically resistant to carbapenems.
Table 6 Correlation of ertapenem consumption with incidence of antibiotic-resistant bacteria
Correlation Coefficient* R2* P-values* Time Lag
Ciprofloxacin-resistant E. coli 0.5349 0.2862 0.111 Zero
Cephalosporin-resistant E. coli 0.6665 0.4442 0.035 Zero
Ciprofloxacin-resistant Klebsiella spp. −0.4393 0.0393 0.583 −1 year
Cephalosporin-resistant Klebsiella spp. −0.6752 0.3514 0.071 −6 months
Ertapenem-resistant E. coli 0.7144 0.5103 0.020 Zero
Ertapenem-resistant Klebsiella spp. 0.5249 0.2755 0.119 Zero
Carbapenem-resistant Acinetobacter baumannii −0.6485 0.0911 0.397 −1 year
Carbapenem-resistant Pseudomonoas aeruginosa 0.5648 0.3190 0.089 Zero
*Correlation coefficient, R2 and P-values are obtained from cross-correlation analysis.
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appropriate indication. In our study, out of 172 secondary
bacteremia cases, 154 cases (89.5%) had microbiological
eradication. Mortality rate in these 172 cases was 13.4%
(23 cases), where 6 died of other causes, and 5 others died
because of concurrent infections, for example disseminated
methicillin-resistant Staphylococcus aureus infection. Four
secondary bacteremia cases treated with ertapenem were
readmitted within 30 days with the same microorganism
isolated; with 3 cases having poor source control previ-
ously, and 1 case was treated with only 5 days of ertape-
nem for ESBL E. coli bacteremia and subsequently oralized
to ciprofloxacin despite intermediate resistance of E. coli to
ciprofloxacin. This could have explained for the recurrence
of bacteremia.
Evidence of ertapenem efficacy in treatment of ESBL
gram-negative bacteremia has been scarce so far, with
only 2 retrospective studies showing favourable clinical
response in treatment of both primary and secondary
bacteremia [24,25]. When compared with antipseudo-
monal carbapenems, treatment with ertapenem for
gram-negative primary bacteremia led to equivalent
mortality rates and bacteriological eradication [26]. It
was observed in our study that out of 57 treatment fail-
ure cases, ertapenem was used for bacteremia in 14
cases; of which, 8 were primary bacteremia cases. For
patients with secondary bacteremia in our study, treat-
ment outcomes were favourable, with a high microbio-
logical eradication rate (89.5%) and a low mortality rate
(13.4%), thereby supporting the use of ertapenem in
secondary bacteremia.
There is a concern that extensive first-line use of erta-
penem will select multi-drug resistant pathogens with
cross-resistance to other carbapenems [5,6]. Based on
our study results, increasing consumption of ertapenem
correlated with subsequent increasing incidences of
ertapenem-resistant Escherichia coli (R2 = 0.5103) sig-
nificantly and carbapenem-resistant Pseudomonas aeru-
ginosa at increasing statistical trend (R2 = 0.3190). This
macroscopic level of observation was also validated by
our observation from the detailed evaluation of 906
cases at microscopic level. While the emergence of
carbapenem-resistant Pseudomonas aeruginosa might be
due to inducible resistance after exposure to ertapenem,
the emergence of ertapenem-resistant Escherichia coli
and Klebsiella spp. is likely to be due to the selection of
an ertapenem-resistant subpopulation (ESBLs with mem-
brane porin loss) that already pre-exist among the ertape-
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Figure 4 Ertapenem Consumption against Pseudomonas aeruginosa.
Table 7 Correlation of ertapenem consumption with consumption of other antibiotics
Antibiotic Correlation Coefficient* R2* P-values* Time Lag
Ciprofloxacin 0.3177 0.10093 0.717 −3 months
Ceftriaxone 0.4695 0.22043 0.657 −3 months
Cefepime −0.6111 0.37344 0.067 3 months
Imipenem −0.5575 0.31081 0.001 Zero
Meropenem 0.2948 0.4092 0.004 6 months
*Correlation coefficient, R2 and P-values are obtained from cross-correlation analysis.
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results of 3 other studies that showed no increased inci-
dence of carbapenem-resistant Pseudomonas aeruginosa
isolates after introduction of ertapenem into the hospital
formularies [9,10,28]. In our retrospective study, a small
proportion of patients developed carbapenem-resistant
Pseudomonas aeruginosa (2.8%), Acinetobacter baumannii
(2.2%), and ESBL enterobacteriaceae (0.9%) within 30 days
of ertapenem therapy initiation. Only data within 30 days
was used for evaluation of infection recurrences in our
study to prevent or reduce the impact of bacterial strains
import from the community and other healthcare centres.
It was noted that the mean duration of hospital stay
was 36.55 ± 45.53 days in our retrospective study. Out
of 906 patients, 40 patients (4.4%) were on ertapenem
for treatment of osteomyelitis or skin abscesses, with
duration of ertapenem ranging from 28 to 42 days.
Twenty-eight patients (3.1%) were treated for intra-
abdominal abscesses, with a median duration of 24 days.
The long hospital stay may have been a risk factor in the
rates of carbapenem-resistant Pseudomonas aerginosa
and Acinetobacter baumannii observed, as also reported
by Falagas et al [29]. However, most patients were initi-
ated on ertapenem early during hospital stay, therefore
ruling out this confounding factor.
While ciprofloxacin and ceftriaxone resistance rates in
Escherichia coli continued to increase, ciprofloxacin and
ceftriaxone resistant Klebsiella spp. incidence densities
surprisingly decreased independently, before the increase
in ertapenem consumption. Hence, the increase in erta-
penem consumption could be attributed to an increase
in cephalosporin and ciprofloxacin resistant Escherichia coli
mainly. An increase in incidence density of community
extended-spectrum beta-lactamase (ESBL)-producing and
quinolone-resistant Escherichia coli isolates may have
contributed to this phenomenon. Pada and co-workers had
found that up to 12% of more than 1,000 emergency de-
partment attendees without previous health care associ-
ation at hospital 2 in 2007 were colonized with ESBL-
positive enterobacteriaceae—the vast majority of which
were Escherichia coli [30]. This was because the extensive
use of ciprofloxacin in community acquired infections had
probably led to a continual increase in incidences of ESBLs
colonization in the community.
The increasing consumption of ertapenem correlated
with subsequent increasing consumption of meropenem,
which may be due to selection for Pseudomonas aerugi-
nosa with ertapenem use. However, increasing consump-
tion of ertapenem correlated with decreasing
consumption of imipenem. This could be due to phys-
ician preference for meropenem in view of relatively
lower incidence of seizures with meropenem as com-
pared to imipenem [31-33]. The consumption of cefe-
pime, in the treatment of ESBLs, was gradually replaced
by ertapenem in our institution as there were high inci-
dences of CTX-M producing Klebsiella spp. and Escheri-
chia coli [34] which could have high minimum
inhibitory concentrations to cefepime [35-37].
There are several limitations to this work. One of the
main limitations of the study was the retrospective nature
of the study. Limitations inherent to retrospective review
include a dependency on previously recorded data, which
may be limited by systematic or recorder bias. Since
data from NARSS [15-21] is extracted primarily from
the hospital microbiology and pharmacy databases, it is
not possible to distinguish between colonization and
infection except when there are blood culture results
(i.e. “bacteremia”). In addition, the study period of 4.5
years may be too short to evaluate true impact of
Figure 5 Ertapenem Consumption against Anti-Pseudomonal Carbapenem Consumption.
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ertapenem on local epidemiology. Nevertheless, it still al-
lows the determination of any broad association between
ertapenem consumption and antibiotic resistance.
In this study, only SGH data on antibiotic prescription,
including ertapenem, and antimicrobial resistance trends
were analyzed, therefore conclusions may not be general-
ized to other hospitals or community. Cross-correlation
analysis of ertapenem consumption and antimicrobial re-
sistance trends was performed without adjusting for pos-
sible confounding factors, such as consumption of other
antibiotics like meropenem and length of hospitalization.
Infection control measures over the same period were also
not assessed, which may have been a contributing factor
to transmission of drug-resistant microorganisms.
Conclusions
In conclusion, ertapenem was used appropriately in SGH, in
terms of dose and indication and had resulted in a high suc-
cessful treatment rate. Increasing ertapenem consumption
ESBL-producing may result in the selection for multi-drug
resistant bacteria, like carbapenem-resistant Pseudomonas
aeruginosa. Hence, it would be prudent to judiciously use
ertapenem for ESBL-producing microorganisms, with ad-
equate dosage.
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